Proceedings of the XLVII Italian Society of Agricultural Genetics - SIGA Annual Congress

Verona, Italy - 24/27 September, 2003

ISBN 88-900622-4-X

 

Poster Abstract - 3.21

 

TOBACCO PLANTS AS BIOFACTORIES FOR THE PRODUCTION OF AN ANTI-HIV VACCINE

 

E. FERRAIOLO*, L. BUONAGURO**, F.M. BUONAGURO**, M.L. TORNESELLO**, L. MONTI*, N. SCOTTI*, S. GRILLO*, T. CARDI*

 

*) CNR-IGV, Institute of Plant Genetics, Res. Div. Portici

cardi@unina.it

**) Viral Oncology, Ist. Naz. Tumori “Fond. G. Pascale”, Napoli

 

 

tobacco, biopharmaceuticals, biofactories, vaccines, transgenic plants

 

Tobacco, an important crop in various Italian Regions, is an attractive plant for the production of Plant Made Pharmaceuticals, since it is a no-food crop and thus there is no risk of cross contamination of the food chain. It has a large biomass and very good response to various biotechnological approaches. Further, its cultivation for the traditional use as drug, subsidized by European Union, does no longer remunerate farmers and it is under close scrutiny.

 

In Western Countries, the HIV, the well known agent of the “Acquired ImmunoDeficiency Syndrome” (AIDS), is presently controlled by anti-retroviral therapeutic strategies (HAART). Nevertheless, the definitive control of the disease is still difficult due to the high frequency of “escape mutants” and the unavailability of the HAART therapy in developing countries. An alternative strategy relies on the development of preventive anti-HIV vaccines. A promising approach is based on the property of the capsid protein Gag to auto-assemble and form Virus-Like Particles (VLPs) displaying several viral epitopes on the surface. Encouraging results have been already obtained by producing VLPs expressing gag-pol-nef and env genes in the baculovirus/insect cell expression system (Buonaguro L. et al. 2001 Antiviral Res. 49, 35-47; Buonaguro L. et al. 2002 Antiviral Res. 54, 189-201).

 

In order to test the feasibility to produce a similar range of viral antigens in plant cells, we recently cloned a modified gag-pol-nef gene construct in an Agrobacterium-based plant expression vector, and the env gene in a plant vector suitable for biolistic transformation. In the former case selection was based on a cointegrated nptII gene conferring kanamycin resistance, whereas in the latter it depended on a hpt gene, determining hygromycin resistance, on a separate plasmid. Expression of both transgenes was driven by the constitutive 35S CaMV promoter.

 

We obtained transgenic plants with both constructs and approaches. In experiments with Agrobacterium tumefaciens, from 30 co-cultivated explants we obtained 23 independent KanR shoots that were also positive to PCR analysis; that is equivalent to a transformation frequency of 0.8 transgenic shoots per explant. In co-transformation experiments using the biolistic approach, we bombarded explants with different molar ratios of two plamids, carrying the hpt and the env genes, respectively. Transformation frequencies ranged from 2.4 to 9.8 independent hpt+ shoots per bombarded explant. Co-transformation frequencies varied from 33 to 57%. Best results, both for the  integration of the marker gene and for the co-transformation efficiency, were obtained with a 1:8 (hpt:env) ratio between the two plasmids.

 

Further molecular characterization (RT-PCR) of transgenic plants indicated that both gag and env genes were transcribed in the tobacco cells, albeit at relatively low levels. Plants with higher production of the transcript could be selected. Analysis of protein expression is under way.